Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3β-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARγ agonist activity

Journal of Molecular Endocrinology

Volumn 32, Issue 2, 2004, Pages 425-436

  Arlt, Weibke ^a   Neogi, Partha ^b   Gross, Coleman ^b   Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Calyx Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; CINNAMIC ACID DERIVATIVE; COUMARIN; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450C17; DEXTROMETHORPHAN; DICLOFENAC; GLUCOSE; INSULIN; MEPHENYTOIN; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENACETIN; PIOGLITAZONE; ROSIGLITAZONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GLUCOSE TRANSPORT; INSULIN SENSITIVITY; MICROSOME; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; YEAST;

17-HYDROXYSTEROID DEHYDROGENASES; 3T3 CELLS; ANIMALS; CELLS, CULTURED; CINNAMATES; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED STRAINS; PPAR GAMMA; STEROID 17-ALPHA-HYDROXYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS);

EID: 2342631940     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0320425     Document Type: Article

References (38)

1. Arlt W, Auchus RJ & Miller WL 2001 Thiazolidinediones but not metformin directly inhibit the steroidogenic enzyme P450c17 and 3β-hydroxysteroid dehydrogenase. Journal of Biological Chemistry 276 16767-16771.
2. Auchus RJ & Miller WL 1999 Molecular modeling of human P450c17 (17α-hydroxylase/17 m20 lyase): insights into reaction mechanisms and effects of mutations. Molecular Endocrinology 13 1169-1182.
3. Auchus RJ, Lee TC & Miller WL 1998 Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. Journal of Biological Chemistry 273 3158-3165.
4. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, & Ghazzi MN 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 86 1626-1632.
5. Baldwin SJ, Clarke SE & Chenery RS 1999 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. British Journal of Pharmacology 48 424-432.
6. Cantello BC, Cawthorne MA, Haig D, Hindley RM, Smith SA & Thurlby PL 1994 The synthesis of BRL 49653 - a novel and potent antihyperglycemic agent. Bioorganic Medicine and Chemistry Letters 4 1181-1184.
7. Crespi CL & Miller PV 1999 The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacology and Therapeutics 84 121-131.
8. Dey D, Medicherla S, Neogi P & Nag B 1999 CLX-0901: a new class of orally active insulin sensitizer. Diabetes 48 A119.
9. Dey D, Neogi P & Nag B 2001 Evidence for the interaction of a small molecule with insulin receptor using surface plasmon resonance. FASEB Journal 15 A526.
10. Dunaif A & Thomas A 2001 Current concepts in the polycystic ovary syndrome. Annual Reviews in Medicine 52 401-419.
11. Dunaif A, Scott D, Finegood D, Quintana B & Whitcomb R 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 81 3299-3306.
12. Ehrmann DA, Barnes RB & Rosenfield RL 1995 Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews 16 322-353.
13. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL & Polonsky KS 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82 2108-2116.
14. Franks S 1995 Polycystic ovary syndrome. New England Journal of Medicine 333 853-861.
15. Frost SC & Lane DM 1985 Evidence for the involvement of vicinal sulfhydryl groups in insulin activated hexose transport by 3T3-L1 adipocytes. Journal of Biological Chemistry 260 2646-2652.
16. Gietz D, St Jean A, Woods RA & Schiestl RH 1992 Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Research 20 1425.
17. Hadfield C, Cashmore AM & Meacock PA 1986 An efficient chloramphenicol-resistance marker for Saccharomyces cerevisiae and Escherichia coli. Gene 45 149-158.
18. Kenworthy KE, Bloomer JC, Clarke SE & Houston JB 1999 CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Pharmacology 48 716-727.
19. Lee TC, Miller WL & Auchus RJ 1999 Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. Journal of Clinical Endocrinology and Metabolism 84 2104-2110.
20. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM & Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry 270 12953-12956.
21. Lin D, Harikrishna JA, Moore CCD, Jones KL & Miller WL 1991 Missense mutation serine106→proline causes 17α-hydroxylase deficiency. Journal of Biological Chemistry 266 15992-15998.
22. Lin D, Black SM, Nagahama Y & Miller WL 1993 Steroid 17α-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 132 2498-2506.
23. Mosome Y, Meguro K, Ikeda H, Hatanaka C, Ot S & Shoda T 1991 Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chemistry and Pharmacology Bulletin 39 1440-1444.
24. Nakajima N, Kakamura S, Tokudome S, Shimada N, Yamazaki H & Yokoi T 1999 Azelastine N-demethylation by cytochrome P-450 CYP3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposal 27 1381-1391.
25. Nakajin S, Shively JE, Yuan PM & Hall PF 1981 Microsomal cytochrome P-450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and c17,20-lyase) associated with one protein. Biochemistry 20 4037-4042.
26. Obach RS 1999 Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposal 27 1350-1339.
27. Olefsky JM 2000 Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. Journal of Clinical Investigation 106 467-472.
28. Pompon D, Louerat B, Bronine A & Urban P 1996 Yeast expression of animal and plant P450s in optimized redox environments. Methods of Enzymology 272 51-64.
29. Primer A 2000 Animal models of diabetes. In Animal Models of Diabetes, pp 63-109. Eds A Sima & E Shafir. London: Harwood Academic.
30. Rendic S & Di Carlo FJ 1997 Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 29 414-580.
31. Rhéaume E, Simard J, Morel Y, Mebarki F, Zachmann M, Forest MG, New MI & Labrie F 1992 Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene. Nature Genetics 1 239-245.
32. Schoonjans K & Auwerx J 2000 Thiazolidinediones: an update. Lancet 355 1008-1010.
33. Shoda T, Mizuno K, Imamiya E, Sugiyama Y, Fujita T & Kawamatsu Y 1982 Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chemistry and Pharmacology Bulletin 30 3580-3600.
34. Spiegelman BM 1998 PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 507-514.
35. Tafuri SR 1996 Troglitazone enhances differentiation, basal glucose uptake and Glut1-protein levels in 3T3-L1 adipocytes. Endocrinology 137 4706-4712.
36. Thomas JL, Myers RP & Strickler RC 1989 Human placental 3 β-hydroxy-5-ene-steroid dehydrogenase and steroidΔ5→ Δ4-ene-isomerase: purification from mitochondria and kinetic profiles, biophysical characterization of the purified mitochondrial and microsomal enzymes. Journal of Steroid Biochemistry 33 209-217.
37. Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M & Yoko T 2000 In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitzone. Xenobiotica 20 61-70.
38. Zuber MX, Simpson ER & Waterman MR 1986 Expression of bovine 17α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 234 1258-1261.